Becton, Dickinson and Company — FY2021 Form 10-K
Reporting period: Fiscal year ended September 30, 2021. Although the request references 2021 Q4, the provided filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary.
Business context and results
BD is a global medical technology company operating through BD Medical, BD Life Sciences and BD Interventional. Annual revenue was $20.248 billion, up 18.3% from $17.117 billion in FY2020 (15.6% on a foreign-currency-neutral basis). Growth reflected recovery from pandemic-related declines, core-product demand, favorable currency translation and approximately $2 billion of COVID-19 diagnostic testing sales.
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $20.248 billion | $17.117 billion |
| Gross margin | 46.6% | 44.3% |
| Operating income | $2.799 billion | $1.484 billion |
| Net income | $2.092 billion | $874 million |
| Diluted EPS | $6.85 | $2.71 |
| Operating cash flow | $4.647 billion | $3.539 billion |
| Capital expenditures | $1.231 billion | $810 million |
| Total debt | $17.610 billion | $17.931 billion |
Operating margin was approximately 13.8%, compared with 8.7% in FY2020; net margin was approximately 10.3%, compared with 5.1%. Operating cash flow less capital expenditures was approximately $3.416 billion. Cash, cash equivalents, restricted cash and short-term investments totaled approximately $2.4 billion at year-end. Current assets were $8.838 billion and current liabilities $6.626 billion. BD paid $1.048 billion in dividends and repurchased $1.750 billion of common stock.
Segments and changes versus prior year
- Medical: Revenue of $9.479 billion, up 9.2%; operating income of $2.583 billion. Medication Delivery Solutions and Pharmaceutical Systems grew strongly; Medication Management Solutions declined, in part because of Alaris pump restrictions and the prior-year comparison.
- Life Sciences: Revenue of $6.530 billion, up 39.7%; operating income of $2.391 billion. Growth was led by COVID-19 testing, alongside recovery in routine diagnostics and laboratory activity. The segment recorded approximately $93 million of excess and obsolete COVID-19 testing inventory expense.
- Interventional: Revenue of $4.239 billion, up 12.7%; operating income of $933 million. Recovery in hospital utilization and demand across the segment supported growth.
Results improved substantially from FY2020, when pandemic-related procedure and testing declines weighed on several businesses. Gross margin benefited from improved demand and product mix, COVID-19 testing sales, and a more favorable comparison for manufacturing overhead. Raw-material and freight inflation, foreign exchange and remediation costs were offsets. FY2021 operating results also included $361 million of product-liability charges, a $158 million gain on sale-leaseback transactions, and $185 million of losses on debt extinguishment.
Outlook, risks and contingencies
- The filing does not provide a clear quantified revenue or earnings forecast. Management expects COVID-19 testing revenue to decline in future periods as infection rates, vaccination and competition affect demand and pricing; it cautions that pandemic-related demand and operating conditions remain uncertain.
- BD expected to complete the proposed Diabetes Care spin-off in the first half of calendar 2022, subject to customary conditions and approvals. The transaction could be delayed or may not deliver expected benefits.
- BD Alaris infusion pumps in the U.S. were being shipped only for medical necessity and recalled-software remediation. Full commercial operations require FDA clearance of a 510(k) submission; timing and outcome were uncertain. BD reported a continuing FDA consent decree and unresolved inspection observations.
- Product-liability reserves were approximately $2.5 billion at September 30, 2021. The filing describes substantial hernia, women’s health and IVC filter claims, and states that additional losses could exceed established accruals. The auditor identified estimation of product-liability reserves as a critical audit matter.
- Other material risk areas include COVID-19 disruptions, supply-chain and labor constraints, inflation, sterilization capacity and ethylene oxide regulation, cybersecurity, reimbursement and pricing pressure, foreign exchange, regulatory compliance, litigation and leverage. The Georgia sterilization consent order required operational changes, including reduced capacity.
- BD reported $17.610 billion of total debt, a 2.4% weighted-average debt cost and compliance with applicable credit-facility covenants. Its $2.75 billion revolving credit facility had no borrowings outstanding at year-end.
Most important facts for investors to verify
- How much future revenue and margin depend on COVID-19 testing, and the pace of normalization in routine diagnostics and procedures.
- FDA progress and timing for Alaris clearance, commercial resumption and any additional remediation costs or enforcement action.
- Developments, settlements, reserve adequacy and potential cash requirements for the approximately $2.5 billion product-liability reserve.
- Spin-off completion, final terms, tax treatment, separation costs and the standalone prospects of Diabetes Care.
- Whether supply-chain, freight and raw-material inflation, sterilization constraints and other costs erode margin recovery.
- Debt maturities and refinancing needs, alongside capital returns, investment spending and cash generation.